Table 1.
Baseline Characteristics of the Study Sample.
| Variable | SGB Injection | Placebo Injection | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean/ N (%) | SD | Min | IQR | Median | Max | N | Mean/ N (%) | SD | Min | IQR | Median | Max | |
| Sex | 5 | 5 | ||||||||||||
| Female | 1 | 20% | 3 | 60% | ||||||||||
| Male | 4 | 80% | 2 | 40% | ||||||||||
| Age (years) | 5 | 43.2 | 9.8 | 34 | 38-48 | 38 | 58 | 5 | 51.6 | 10.7 | 34 | 51–59 | 53 | 61 |
| Weight (kg) | 5 | 69.6 | 6.6 | 59 | 68–74.8 | 71 | 75 | 5 | 83.4 | 22.6 | 51 | 77–104 | 79 | 106 |
| Height (cm) | 5 | 170.6 | 10.4 | 155 | 167–175 | 173 | 183 | 5 | 169.4 | 14.6 | 145 | 170–178 | 171 | 183 |
| HAMD score | 5 | 21 | 3.5 | 18 | 19–21 | 20 | 27 | 5 | 22.2 | 4.2 | 18 | 20–23 | 21 | 29 |
| Antidepressant use | ||||||||||||||
| SSRI | 0 | 0% | 1 | 20% | ||||||||||
| SNRI | 1 | 20% | 1 | 20% | ||||||||||
| TCA | 0 | 0% | 2 | 40% | ||||||||||
| MAOI | 1 | 20% | 0 | 0% | ||||||||||
| Atypical antidepressant | 2 | 40% | 0 | 0% | ||||||||||
| Atypical antipsychotic | 0 | 0% | 1 | 20% | ||||||||||
| Other | 3 | 60% | 1 | 20% | ||||||||||
| Comorbidities | ||||||||||||||
| Panic Disorder | 1 | 20% | 3 | 60% | ||||||||||
| Agoraphobia | 1 | 20% | 2 | 40% | ||||||||||
| Social phobia | 0 | 0% | 3 | 60% | ||||||||||
| Generalized Anxiety Disorder | 2 | 40% | 3 | 60% | ||||||||||
| Obsessive-compulsive Disorder | 0 | 0% | 1 | 20% | ||||||||||
| Anorexia | 0 | 0% | 1 | 20% | ||||||||||
| Bulimia | 0 | 0% | 0 | 0% | ||||||||||
Abbreviations: SGB, stellate ganglion block; IQR, interquartile range; HAMD, Hamilton Depression Rating Scale; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitors; TCA, tricyclic antidepressants; MAOI, monoamine oxidase inhibitors.